10x Genomics (TXG) Research & Development (2018 - 2026)

10x Genomics has disclosed Research & Development across 9 years of filings, most recently posting $56.8 million for Q1 2026.

• Research & Development for Q1 2026 came in at $56.8 million, down 11.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $231.2 million (down 11.17% YoY), and the FY2025 annual result was $238.6 million, down 9.85% from the prior year.
• Research & Development came in at $56.8 million for Q1 2026 at 10x Genomics, up from $56.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $71.5 million in Q2 2023 to a low of $56.0 million in Q4 2025.
• The 5-year median for Research & Development is $65.3 million (2023), against an average of $64.5 million.
• Across the five-year window, Research & Development jumped 52.99% in 2022 and slipped 16.42% in 2025, its largest moves.
• 10x Genomics' Research & Development stood at $63.6 million in 2022, then climbed by 2.6% to $65.3 million in 2023, then gained by 2.61% to $67.0 million in 2024, then decreased by 16.42% to $56.0 million in 2025, then increased by 1.57% to $56.8 million in 2026.
• The last three Research & Development figures came in at $56.8 million (Q1 2026), $56.0 million (Q4 2025), and $57.2 million (Q3 2025), per Business Quant data.